Skip to main content
. 2012 Mar 8;1:20. doi: 10.1186/2046-4053-1-20

Table 5.

Arousal index (events/hour) in randomized controlled trials of APAP versus CPAP

Study
PMID
Baseline AHI (SD)
[eligibility]
Baseline ESS (SD) Duration (design) Interventions Number analyzed Baseline (SD) Change
(final)
Net difference
or difference
95% CIa P Dropout (%) Study quality
d'Ortho 2000 [32]
11035671
58 (6)
[≥10]
12.7 (5.3) 2 months
(XO)
APAP 25 45.6
(25.8)
-30.1 1.8 nd NS 0 B
CPAP 25 45.6
(25.8)
-31.9
Damjanovic 2009 [10]
19129293
44 (25)
[≥15]
8.8 (5.18) 3 months
(PL)
APAP 46 30.6 (22.4) -18.3 -0.2 -7.92 to 7.52 nd 8 B
CPAP 46 34.5
(21.0)
-18.1
9 months
(PL)
APAP 34 30.6 (22.4) -17.7 3.6 -4.09 to 11.29 nd 22
CPAP 44 34.5
(21.0)
-21.3
Galetke 2008 [12]
17148931
33 (19)
[> 10]
10.3 (5.7) 2 months
(XO)
APAP 20 17.6 (9.2) -4.0 1.0 -2.52 to 4.52 nd nd C
CPAP 20 17.6 (9.2) -5.0
Hussain 2004 [20]
15072173
47 (36)
[> 15]
11.1 (6.4) 1 month
(XO)
APAP 10 17.3 (17.7) -11.4 1.0 -2.5 to 4.5 nd 0 C
CPAP 10 17.3 (17.7) -12.4
Konermann 1998 [31]
9515848
38 (14)
[> 20}
nd 3 to 6 months
(PL)
APAP 25 16.9 (10.5) -9.5 -3.3 -6.6 to 0b < 0.05 4 B
CPAP 23 13.3
(13.3)
-6.2
Nolan 2007 [14]
17326544
15 (8)
[≥5)
12.3 (4) 2 months
(XO)
APAP 29 16.0 (14.0) -14.0 -3.0 -5.7 to -0.29b 0.03 15 B
CPAP 29 16.0 (14.0) -11.0
Planes 2003 [29]
12683473
59 (17)
[≥30]
15.1 (3.9) 2 months
(PL)
APAP 16 44.4 (19.1) 3.3 -7.14 to 12.74 nd 14 C
CPAP 14 48.5 (14.2)
Randerath 2001 [26]
11254519
35 (26)
[≥10]
11.1 (5.1) 1.5 months
(XO)
APAP 52 34 (21.7) -23.1 -1.7 -3.7 to 0.3 nd 12 B
CPAP 52 34 (21.7) -21.4
Resta 2004 [24]
15679008
47 (11)
[> 30]
13.9 (3.2) 1 month
(PL)
APAP 10 43.1 (11.9) -35.7 0.1 -8.29 to 8.49 nd 0 C
CPAP 10 43.1 (9.1) -35.8
Sériès 1997 [27]
9341056
44 (20)
[nd]
15.5 (4.5) 0.75 months
(PL)
APAPc 12 nd nd - - NS 0 C
CPAP 12 nd nd
APAPd 12 nd nd - - NS
CPAP 12 nd nd

AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP: continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; XO: cross-over design. aEstimated from reported data. bEstimated from reported P value. cEstimated effective pressure. dMeasured effective pressure.